SubHero Banner

Vowst (fecal microbiota spores, live-brpk) – New orphan drug approval

April 26, 2023 - The FDA announced the approval of Seres Therapeutics’ Vowst (fecal microbiota spores, live-brpk), to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).

Download PDF